BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HRS-7085 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HRS-7085\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07229950-30@assetmemo.bio
DTSTAMP:20261121T005706Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRS-7085: Phase 2 readout est. (NCT07229950)
DESCRIPTION:HRS-7085\, phase 2\, Ulcerative Colitis.\nStudy: A Phase 2 Clin
 ical Study to Evaluate the Efficacy\, Safety\, and Pharmacokinetics of HRS
 -7085 Tablets in Patients With Inflammatory Bowel Disease\nEstimated prima
 ry completion: December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/hrs-7085#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07229950
URL:https://assetmemo.bio/drug/hrs-7085#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07760831-30@assetmemo.bio
DTSTAMP:20261121T005706Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:HRS-7085: Phase 1 readout est. (NCT07760831)
DESCRIPTION:HRS-7085\, phase 1\, Ulcerative Colitis.\nStudy: A Trial of HRS
 -7085 Tablets in Patients With Moderate to Severe Active Ulcerative Coliti
 s\nEstimated primary completion: April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/hrs-7085#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07760831
URL:https://assetmemo.bio/drug/hrs-7085#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
